{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,3]],"date-time":"2022-04-03T07:11:20Z","timestamp":1648969880816},"reference-count":14,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2017,12,1]],"date-time":"2017-12-01T00:00:00Z","timestamp":1512086400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Therapies"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1016\/j.therap.2017.03.003","type":"journal-article","created":{"date-parts":[[2017,5,30]],"date-time":"2017-05-30T23:45:35Z","timestamp":1496187935000},"page":"643-647","source":"Crossref","is-referenced-by-count":1,"title":["Success of tardive electroconvulsive therapy sessions after loxapine-induced malignant syndrome in the context of very poor metabolisation"],"prefix":"10.1016","volume":"72","author":[{"given":"Juliette","family":"Descoeur","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laurent","family":"Philibert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kevin","family":"Chalard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J\u00e9r\u00f4me","family":"Attal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pierre","family":"Petit","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kada","family":"Klouche","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mathieu","family":"Olivier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.therap.2017.03.003_bib0075","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1055\/s-0031-1286287","article-title":"AGNP consensus guidelines for therapeutic drug monitoring in psychiatry: Update 2011","volume":"44","author":"Hiemke","year":"2011","journal-title":"Pharmacopsychiatry"},{"key":"10.1016\/j.therap.2017.03.003_bib0080","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1007\/BF03220182","article-title":"Interspecies variability and drug interactions of loxapine metabolism in liver microsomes","volume":"28","author":"Bun","year":"2003","journal-title":"Eur J Drug Metab Pharmacokinet"},{"key":"10.1016\/j.therap.2017.03.003_bib0085","first-page":"210","article-title":"Characterization of loxapine human metabolism","volume":"40","author":"Huie","year":"2008","journal-title":"Drug Metab Rev"},{"key":"10.1016\/j.therap.2017.03.003_bib0090","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.jpba.2011.09.020","article-title":"Investigation of the disposition of loxapine, amoxapine and their hydroxylated metabolites in different brain regions, CSF and plasma of rat by LC\u2013MS\/MS","volume":"58","author":"Wong","year":"2012","journal-title":"J Pharm Biomed Anal"},{"key":"10.1016\/j.therap.2017.03.003_bib0095","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1002\/humu.10280","article-title":"CYP2D6 genotyping strategy based on gene copy number determination by TaqMan real-time PCR","volume":"22","author":"Schaeffeler","year":"2003","journal-title":"Hum Mutat"},{"key":"10.1016\/j.therap.2017.03.003_bib0100","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1002\/jps.2600680224","article-title":"GLC analysis of loxapine, amoxapine and their metabolites in serum and urine","volume":"68","author":"Cooper","year":"1979","journal-title":"J Pharm Sci"},{"key":"10.1016\/j.therap.2017.03.003_bib0105","unstructured":"CYP2D6 nomenclature allele. http:\/\/www.cypalleles.ki.se\/cyp2d6.htm [accessed 15\u00a0May\u00a02017]."},{"key":"10.1016\/j.therap.2017.03.003_bib0110","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1192\/bjp.159.4.572","article-title":"Neuroleptic malignant syndrome secondary to loxapine","volume":"159","author":"Chong","year":"1991","journal-title":"Br J Psychiatry"},{"key":"10.1016\/j.therap.2017.03.003_bib0115","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1093\/jat\/24.7.638","article-title":"Loxapine intoxication: case report and literature review","volume":"24","author":"Mazzola","year":"2000","journal-title":"J Anal Toxicol"},{"issue":"2","key":"10.1016\/j.therap.2017.03.003_bib0120","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1111\/bcp.12441","article-title":"Addressing phenoconversion: the Achilles\u2019 heel of personalized medicine","volume":"79","author":"Shah","year":"2015","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.therap.2017.03.003_bib0125","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1097\/00007691-199906000-00017","article-title":"Small effects of valproic acid on the plasma concentrations of clozapine and its major metabolites in patients with schizophrenic or affective disorders","volume":"21","author":"Facciol\u00e0","year":"1999","journal-title":"Ther Drug Monit"},{"key":"10.1016\/j.therap.2017.03.003_bib0130","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1055\/s-2007-1004591","article-title":"Estimating the size of the effects of comedications on plasma clozapine concentrations using a model that controls for clozapine doses and confounding variables","volume":"41","author":"Diaz","year":"2008","journal-title":"Pharmacopsychiatry"},{"key":"10.1016\/j.therap.2017.03.003_bib0135","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1055\/s-0034-1371866","article-title":"Can valproic acid be an inducer of clozapine metabolism?","volume":"47","author":"Diaz","year":"2014","journal-title":"Pharmacopsychiatry"},{"key":"10.1016\/j.therap.2017.03.003_bib0140","doi-asserted-by":"crossref","first-page":"D980","DOI":"10.1093\/nar\/gkt1113","article-title":"ClinVar: public archive of relationships among sequence variation and human phenotype","volume":"42","author":"Landrum","year":"2014","journal-title":"Nucleic Acids Res"}],"container-title":["Therapies"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0040595717300872?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0040595717300872?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,4,3]],"date-time":"2019-04-03T12:14:14Z","timestamp":1554293654000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0040595717300872"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,12]]},"references-count":14,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["S0040595717300872"],"URL":"https:\/\/doi.org\/10.1016\/j.therap.2017.03.003","relation":{},"ISSN":["0040-5957"],"issn-type":[{"value":"0040-5957","type":"print"}],"subject":[],"published":{"date-parts":[[2017,12]]}}}